Eurobio Scientific's Activity for the First Half of 2019: Strong Growth of Sales
ACTIVITY FOR THE FIRST HALF OF 2019: STRONG GROWTH OF SALES
Consolidated half-year turnover up 18% at € 29.5 million
mainly driven by new distributions and new customers
Paris, July 23 2019 – 17:45 pm
Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), the leading French group in the field of in vitro medical diagnostics and life sciences, presents today its consolidated half-year turnover as at June 30, 2019.
Strong growth of + 18% at € 29.5 million
Driven by new distribution contracts put in place during the second half of 2018, with partners like Quidel for its Triage range, and new customers such as BioGroup-LCD, the Group's turnover increased by 18%, reaching € 29.5 million for the first half of 2019. This growth rate is much higher than the rate observed for the first semester of 2018 (+ 2%) and the rate of growth of the in vitro diagnostics sector in France. It reinforces the group's goal of double-digit growth in 2019.
| in million euros | H1 2019 | H1 2018 | Chg. | ||||
| Total | 29.5 | 25.1 | +18% | ||||
| Unaudited figures The turnover breakdown by activity will be confirmed when 2019 mid-year results will be published | |||||||
During the first half of 2019, activity is once again driven by the Diseases division (diagnostics and treatment effectiveness monitoring tests for biology laboratories), which sales are growing strongly at € 16.3 million, about 55% of overall sales. Sales for the Transplantation division stabilized at € 10.3 million (around 35% of global sales) after a decline in 2018. In the Research Products division, sales also grew at 2%, reaching € 9 million and remaining close to 10% of the Group's global sales.
"Our sales are growing, driven again by the infectious diseases segment, particularly by molecular biology. Although sales remain traditionally better during the first semester, this performance allows us to continue to anticipate good growth over the year, and confirms our objective of an overall turnover increase of 25% over three years, i.e. close to € 60 million in 2020." says Jean-Michel Carle, Chairman and Chief Executive Officer of Eurobio Scientific.
Next Financial Meeting
2019 half-year results: October 15 2019
| About Eurobio Scientific Eurobio Scientific (ex Diaxonhit) is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 120 employees and two production units based in the Paris region and in the United States. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices. Symbol : ALERS - ISIN Code: FR0013240934 - Reuters : ALERS.PA - Bloomberg : ALERS:FP |
Attachment
